The secondary hyperparathyroidism treatment market is expanding due to rising chronic kidney disease (CKD) prevalence, broader usage of calcimimetics such as cinacalcet and etelcalcetide, and enhanced adoption of vitamin D analogs and parathyroidectomy protocols. https://www.datamintelligence.com/research-report/secondary-hyperparathyroidism-treatment-market